A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease

Principal Investigator

Benjamin Ehst

Study Purpose

The purpose of this study is to learn about the effects of the study drug, when compared to NB-UVB (narrow-band ultraviolet B) phototherapy or placebo (an inactive substance that may resemble an active substance but has no medical value) injection on inflammation and heart disease risk factors.

Medical Condition(s)

Moderate to severe plaque psoriasis

Eligibility Criteria

18 years of age and older.
Moderate to severe plaque psoriasis.

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

Subjects will be in this study for 12 weeks. If randomized to the phototherapy group, there will be up to 40 visits. If randomized to the study drug group, there would be up to 11 visits.

Minors Included



Maureen Keene 503-228-7350


National Heart, Lung, and Blood Institute (NIH)

Recruitment End


Compensation Provided



Depending on the group subjects enter and the number of visits they complete, they will be compensated a maximum of either $440 or $940. Subjects will be compensated $20 to offset travel and other indirect costs for participating. Visits in which subjects receive an FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography/computed tomography) scan will pay $110 per visit.

Go Back